Contact
searchSearch
HMP Global
Login

Major Depressive Disorder Topic Center

A man looks out a window
News
Adjunctive Vagus Nerve Stimulation Shows Durable Benefit in Treatment-Resistant Depression
01/20/2026
Maria Mantas
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study...
01/20/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network
brain illustration
News
Blood-Brain Biomarker Signatures Differentiate Early Depression and Psychosis
12/18/2025
Maria Mantas
An analysis from the multicenter PRONIA consortium reports that integrated peripheral inflammatory markers and whole-brain gray matter volumes can distinguish early-stage depression from psychosis.
An analysis from the multicenter PRONIA consortium reports that integrated peripheral inflammatory markers and whole-brain gray matter volumes can distinguish early-stage depression from psychosis.
An analysis from the multicenter...
12/18/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves First At-Home tDCS Treatment for Major Depressive Disorder
12/16/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug...
12/16/2025
Psych Congress Network
laptop
News
Message-Based Therapy Shows Comparable Benefit to Video Sessions for Depression
11/11/2025
Maria Mantas
Adults with depression experienced similar treatment effects from asynchronous, message-based psychotherapy (MBP) and video-based psychotherapy (VBP), according to study results. 
Adults with depression experienced similar treatment effects from asynchronous, message-based psychotherapy (MBP) and video-based psychotherapy (VBP), according to study results. 
Adults with depression...
11/11/2025
Psych Congress Network
quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Lumateperone Indication for Major Depressive Disorder
11/07/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug...
11/07/2025
Psych Congress Network
woman with depression
News
Sertraline May Improve Core Depressive Symptoms Within 2 Weeks, Analysis Finds
11/05/2025
Maria Mantas
A secondary analysis of the 2019 PANDA trial found that sertraline improved core symptoms of depression at as early as 2 weeks of treatment, suggesting a faster-acting benefit than previously thought.
A secondary analysis of the 2019 PANDA trial found that sertraline improved core symptoms of depression at as early as 2 weeks of treatment, suggesting a faster-acting benefit than previously thought.
A secondary analysis of the 2019...
11/05/2025
Psych Congress Network
black and white photo of a man
News
Prenatal Lead Exposure Linked to MDD, Anxiety Symptoms in Later Life
10/28/2025
Maria Mantas
Early exposure to lead, particularly in the third trimester of pregnancy, was associated with a higher risk of major depressive disorder and anxiety symptoms in later life, according to cohort study results.
Early exposure to lead, particularly in the third trimester of pregnancy, was associated with a higher risk of major depressive disorder and anxiety symptoms in later life, according to cohort study results.
Early exposure to lead,...
10/28/2025
Psych Congress Network
man looking out of a window
News
Esmethadone Shows Potential in MDD Patients With Antidepressant Tolerance
10/24/2025
Maria Mantas
According to a recent post hoc analysis, esmethadone (REL-1017) may be an effective adjunctive treatment for patients with major depressive disorder (MDD) and antidepressant tolerance/tachyphylaxis (AT). 
According to a recent post hoc analysis, esmethadone (REL-1017) may be an effective adjunctive treatment for patients with major depressive disorder (MDD) and antidepressant tolerance/tachyphylaxis (AT). 
According to a recent post hoc...
10/24/2025
Psych Congress Network

News

A man looks out a window
News
Adjunctive Vagus Nerve Stimulation Shows Durable Benefit in Treatment-Resistant Depression
01/20/2026
Maria Mantas
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study...
01/20/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network
brain illustration
News
Blood-Brain Biomarker Signatures Differentiate Early Depression and Psychosis
12/18/2025
Maria Mantas
An analysis from the multicenter PRONIA consortium reports that integrated peripheral inflammatory markers and whole-brain gray matter volumes can distinguish early-stage depression from psychosis.
An analysis from the multicenter PRONIA consortium reports that integrated peripheral inflammatory markers and whole-brain gray matter volumes can distinguish early-stage depression from psychosis.
An analysis from the multicenter...
12/18/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves First At-Home tDCS Treatment for Major Depressive Disorder
12/16/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug...
12/16/2025
Psych Congress Network
laptop
News
Message-Based Therapy Shows Comparable Benefit to Video Sessions for Depression
11/11/2025
Maria Mantas
Adults with depression experienced similar treatment effects from asynchronous, message-based psychotherapy (MBP) and video-based psychotherapy (VBP), according to study results. 
Adults with depression experienced similar treatment effects from asynchronous, message-based psychotherapy (MBP) and video-based psychotherapy (VBP), according to study results. 
Adults with depression...
11/11/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Lumateperone Indication for Major Depressive Disorder
11/07/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug...
11/07/2025
Psych Congress Network
woman with depression
News
Sertraline May Improve Core Depressive Symptoms Within 2 Weeks, Analysis Finds
11/05/2025
Maria Mantas
A secondary analysis of the 2019 PANDA trial found that sertraline improved core symptoms of depression at as early as 2 weeks of treatment, suggesting a faster-acting benefit than previously thought.
A secondary analysis of the 2019 PANDA trial found that sertraline improved core symptoms of depression at as early as 2 weeks of treatment, suggesting a faster-acting benefit than previously thought.
A secondary analysis of the 2019...
11/05/2025
Psych Congress Network
black and white photo of a man
News
Prenatal Lead Exposure Linked to MDD, Anxiety Symptoms in Later Life
10/28/2025
Maria Mantas
Early exposure to lead, particularly in the third trimester of pregnancy, was associated with a higher risk of major depressive disorder and anxiety symptoms in later life, according to cohort study results.
Early exposure to lead, particularly in the third trimester of pregnancy, was associated with a higher risk of major depressive disorder and anxiety symptoms in later life, according to cohort study results.
Early exposure to lead,...
10/28/2025
Psych Congress Network
man looking out of a window
News
Esmethadone Shows Potential in MDD Patients With Antidepressant Tolerance
10/24/2025
Maria Mantas
According to a recent post hoc analysis, esmethadone (REL-1017) may be an effective adjunctive treatment for patients with major depressive disorder (MDD) and antidepressant tolerance/tachyphylaxis (AT). 
According to a recent post hoc analysis, esmethadone (REL-1017) may be an effective adjunctive treatment for patients with major depressive disorder (MDD) and antidepressant tolerance/tachyphylaxis (AT). 
According to a recent post hoc...
10/24/2025
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Antidepressant Use Not Linked to Worse Traumatic Brain Injury Outcomes
02/03/2026
Brionna Mendoza
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study...
02/03/2026
Psych Congress Network
A frustrated man works on a laptop
News
Frequent Generative AI Use Linked to Increased Depressive Symptoms
01/23/2026
Maria Mantas
Daily or more frequent generative AI use was associated with higher depressive symptom scores on the PHQ-9 compared with nonuse in a large US survey.
Daily or more frequent generative AI use was associated with higher depressive symptom scores on the PHQ-9 compared with nonuse in a large US survey.
Daily or more frequent...
01/23/2026
Psych Congress Network
a man holds his head in his hands
News
Cohort Study Finds Increased Suicide Risk in Survivors of Traumatic Injury
01/21/2026
Maria Mantas
Patients discharged alive after traumatic injury had a 9-fold higher risk of suicide than the general population 2 years after hospitalization, according to cohort study findings.
Patients discharged alive after traumatic injury had a 9-fold higher risk of suicide than the general population 2 years after hospitalization, according to cohort study findings.
Patients discharged alive after...
01/21/2026
Psych Congress Network
A man looks out a window
News
Adjunctive Vagus Nerve Stimulation Shows Durable Benefit in Treatment-Resistant Depression
01/20/2026
Maria Mantas
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study...
01/20/2026
Psych Congress Network
a depressed teen adolescent holds head in hands crying upset sad major depression
News
Omega-3 Supplements Show No Benefit for Pediatric Major Depression in RCT
01/20/2026
Brionna Mendoza
A multicenter randomized clinical trial found that adding omega-3 fatty acid supplements to psychotherapy did not improve outcomes in children and adolescents with moderate-to-severe major depression.
A multicenter randomized clinical trial found that adding omega-3 fatty acid supplements to psychotherapy did not improve outcomes in children and adolescents with moderate-to-severe major depression.
A multicenter randomized...
01/20/2026
Psych Congress Network
brain
News
Several Noninvasive Brain Stimulation Modalities Show Benefit for Treatment-Resistant Schizophrenia
01/19/2026
Maria Mantas
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
A large network meta-analysis...
01/19/2026
Psych Congress Network
US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
illustration of a brain
News
Meta-Analysis Confirms Processing Speed as Core Cognitive Deficit in Schizophrenia
01/12/2026
Maria Mantas
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of...
01/12/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network

Quizzes

quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network
quiz
Quiz
Oral Fluoxetine Dosing for Adults With Major Depressive Disorder
06/12/2025
Meagan Thistle
Test your psychopharmacology knowledge: What is the recommended starting dose of oral fluoxetine for MDD in adults? The maximum dose should not exceed how many mg per day?
Test your psychopharmacology knowledge: What is the recommended starting dose of oral fluoxetine for MDD in adults? The maximum dose should not exceed how many mg per day?
Test your psychopharmacology...
06/12/2025
Psych Congress Network
stacked blocks that spell out the word "quiz"
Quiz
Initial Treatment Approach for Adults in Acute Phase MDD in Ambulatory Care
04/17/2025
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial...
04/17/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
DSM-5
Quiz
How does the DSM-5 define 'remission' in MDD?
12/13/2024
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of...
12/13/2024
Psych Congress Network
DSM-5
Quiz
How does the chronicity of depressive symptoms affect MDD treatment and outcomes?
12/11/2024
Meagan Thistle
12/11/2024
Psych Congress Network
quiz
Quiz
What is esketamine indicated to treat?
12/02/2024
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive...
12/02/2024
Psych Congress Network
quiz
Quiz
Key Barriers to Tardive Dyskinesia Diagnosis
11/18/2024
The key barriers to a tardive dyskinesia diagnosis DID NOT include which of the following, according to data presented in a poster at Psych Congress 2024? Take the quiz now!
The key barriers to a tardive dyskinesia diagnosis DID NOT include which of the following, according to data presented in a poster at Psych Congress 2024? Take the quiz now!
The key barriers to a tardive...
11/18/2024
Psych Congress Network
pop quiz
Quiz
Esketamine Dosing Schedule for Treatment-Resistant Depression
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and...
10/01/2024
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Brain Aging in Schizophrenia
01/22/2026
Maria Mantas
Test your knowledge of recent research with this quick quiz!
Test your knowledge of recent research with this quick quiz!
Test your knowledge of recent...
01/22/2026
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet
Guidelines Quiz
Medication Monitoring in Patients With BPD
01/20/2026
Brionna Mendoza
Test your knowledge of APA guidelines with this quiz!
Test your knowledge of APA guidelines with this quiz!
Test your knowledge of APA...
01/20/2026
Psych Congress Network
Mark Olfson, MD, MPH
Quiz
Telemental Health Use Patterns
01/16/2026
Maria Mantas
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the...
01/16/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Stimulants and Psychosis Risk in ADHD
12/22/2025
Maria Mantas
Do you remember the findings from this systematic review?
Do you remember the findings from this systematic review?
Do you remember the findings...
12/22/2025
Psych Congress Network
Joseph Goldberg, MD
Quiz
Diagnosing Mixed Features in Bipolar Disorder
12/03/2025
Joseph F. Goldberg, MD
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Depression, Inflammation, and Insomnia
11/19/2025
Brionna Mendoza
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
11/19/2025
Psych Congress Network
quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network
a teenager's hand putting a bag of white pills into another teenager's hand.
Quiz
Test Your Knowledge – Understanding Abuse Potential Across ADHD Therapies: What Clinicians Need to Know
10/23/2025
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it...
10/23/2025
Psych Congress Network
Edward Kaftarian, MD
Quiz
Building Patient Rapport in Telepsychiatry
10/09/2025
Edward Kaftarian, MD
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's...
10/09/2025
Psych Congress Network
A woman sleeping peacefully
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 3)
10/09/2025
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if...
10/09/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use